Latest / China Economy with Fexingo: Beijing's Policies, Trade, and Asia-Pacific Markets / How Chinas Fentanyl Crackdown Disrupts Global Drug Trafficking
Transcript
- Lucas: So last week, the DEA announced a major seizure of fentanyl precursor chemicals that originated in China. And that got me thinking about a story we've been tracking but haven't really dug into: how China's 2019 decision to schedule all fentanyl-related substances as controlled chemicals has actually reshaped the global drug trade. Luna: Is that the move where Beijing basically said 'anything that could be used to make fentanyl is now illegal'? I remember it was a big deal at the time, but I haven't seen much follow-up. Lucas: Exactly. In May 2019, China added all fentanyl-related substances — not just a list, but entire classes — to its controlled chemicals list. That was unprecedented. And it came after intense pressure from the Trump administration, which was pointing fingers at Chinese labs for supplying the precursors that were killing tens of thousands of Americans every year. Luna: And did it actually work? I mean, we still hear about fentanyl deaths, but I recall the numbers have come down from the peak. Lucas: They have. US overdose deaths from synthetic opioids peaked at around 75,000 in 2021. By 2024, that number had dropped to about 60,000. Still horrific, but a real decline. And a big part of that is supply-side pressure. China's crackdown has made it much harder to get the precursor chemicals in bulk. Luna: So what specifically changed? I know China has always had some chemical controls, but this was a blanket ban. Lucas: Right. Before 2019, Chinese companies could legally export precursor chemicals like ANPP or 4-ANPP — the building blocks of fentanyl — as long as they weren't obviously for drug production. Enforcement was spotty. After the scheduling, those same chemicals became illegal to manufacture, sell, or export without special permits. And China started sharing data with the DEA in a way they hadn't before. Luna: I've read that seizures of precursors from China have gone up dramatically. Do we have a number on that? Lucas: According to the DEA, seizures of Chinese-origin fentanyl and its precursors increased by over 300% between 2020 and 2025. And the price of fentanyl on US streets has spiked roughly 40% in that period, which suggests supply is tighter. That's a classic market signal. Luna: Forty percent — that's significant. But doesn't it also mean that cartels and other labs just find workarounds? Lucas: They do. And that's the fascinating part. The crackdown didn't eliminate fentanyl; it changed the geography of production and the chemistry. We're now seeing a rise in what are called 'novel synthetic opioids' — drugs like isotonitazene, which is even more potent than fentanyl. Chinese chemists have been developing these new compounds that aren't explicitly covered by the 2019 scheduling. Luna: So it's a cat and mouse game. They ban one molecule, the labs tweak it slightly and call it something else. Lucas: Exactly. But China has also been proactive in adding new substances to the controlled list quickly. In 2024, they scheduled isotonitazene and several analogues. So the enforcement is adaptive, but it's never going to be perfect. The other big shift is that some precursor production has moved to India and Southeast Asia, where controls are looser. Luna: And the us china trade war complicates everything. I mean, we're in a period of tariffs and mutual suspicion. How does that affect cooperation on drug enforcement? Lucas: It's a paradoxical area. On one hand, the overall relationship is adversarial. On the other, both countries have a clear interest in stopping fentanyl. The US is the biggest consumer market, and China doesn't want to be seen as the source of a public health crisis. So there's still a working channel between the DEA and China's National Narcotics Control Commission, even as trade negotiators fight over tariffs. Luna: I remember reading that during the 2025 trade negotiations, there was a specific clause about fentanyl cooperation. Did that go anywhere? Lucas: It did. The Phase Two talks included a memorandum of understanding on information sharing and joint operations. Since then, there have been several coordinated busts. Just last month, Chinese authorities raided a lab in Guangdong that was producing precursor chemicals for a Mexican cartel. That's direct cooperation. Luna: So the trade war hasn't killed this partnership entirely. That's actually somewhat hopeful. Lucas: It is. But there's a cynical view too. Some analysts argue that China uses this cooperation as leverage — a bargaining chip in broader negotiations. 'We'll help you on fentanyl if you go easy on semiconductors.' I don't think it's that transactional, but there's probably some truth to it. Luna: Let's zoom out. What does this mean for the economics of the drug trade? If fentanyl becomes harder to make, do people switch to other drugs? Lucas: That's the big question. There's evidence that when fentanyl supply tightens, some users shift to heroin or meth. But those have their own supply chains. What we're seeing is a diversification of synthetic opioids. Chinese labs are now producing dozens of new analogues that skirt the law. Enforcement is always playing catch-up. Luna: And on the US side, the response has been more treatment and harm reduction. But that's expensive. Lucas: Right. The economic burden of the opioid crisis is estimated at over one trillion dollars annually in the US — healthcare costs, lost productivity, criminal justice. So even a 20% reduction in overdose deaths saves tens of billions. China's cooperation, imperfect as it is, has real economic value. Luna: It's interesting that this is one area where Beijing and Washington can still find common ground. Maybe that's a lesson for other issues. Lucas: Maybe. But it's also a reminder that public health crises don't respect borders. And the drug trade is incredibly adaptive. The moment you close one door, another opens in a different country or a different molecule. Luna: So where do we go from here? What's the next frontier? Lucas: I think we'll see more focus on precursor chemicals that aren't just for fentanyl but for a whole range of synthetic drugs. And more international coordination, maybe through the UN. China has been pushing for a global scheduling system. If that happens, it could make enforcement more consistent. But it requires trust, which is in short supply. Luna: Speaking of trust, this show is built on trying to make complex topics like this make sense without any ads or corporate sponsors. And that's only possible because some listeners choose to support us directly. Lucas: Yeah, it's a small thing, but if you've found value in episodes like this one — where we dig into a specific policy and its real-world effects — you can help keep the show going. It's at buy me a coffee dot com slash fexingo. No pressure, just a way to keep the conversations ad-free. Luna: And honestly, even just telling a friend about the show helps. We're grateful either way. Lucas: Alright, back to the synthetic opioid story. One more thing I want to highlight: the role of the dark web. Chinese labs have been using encrypted marketplaces to sell their new analogues directly to US buyers, bypassing traditional cartels. That's a whole new layer of complexity. Luna: So you have to follow not just the chemistry but the crypto transactions. That's a challenge for law enforcement. Lucas: Exactly. And that's where the next phase of this story is heading. China's cooperation on chemical control is one piece, but the digital trade in drugs is growing. The DEA has been training Chinese cybercrime units to track blockchain transactions. It's a whole new front. Luna: So the cat and mouse game just gets more sophisticated. But at least there's a mouse. Lucas: There is. And for now, that cooperation, however fragile, is making a difference. The numbers show it: fewer deaths, higher prices, more seizures. It's not a victory, but it's progress.